Addition of pertuzumab to traztuzumab + docetaxel added almost 16 months to overall survival compared to those who didn't receive pertuzumab.
Regional disparities in cancer drug access have complex causes, including bureaucratic differences and variation in health care spending.
[Cancer Control] Research derived from phase 1 clinical trials can be vital to the development of new treatments. There are long-lasting positive and negative impacts on those patients who choose to participate in phase 1 clinical trials, but participant safety is a priority.
[Cancer Management and Research] Although thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages still proves to be a therapeutic challenge. In the last several years, new therapeutic strategies have emerged.
[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). The etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) are discussed.
This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).
Table of Contents
Slide 3: Indication, Dosage, ...
This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.
Table of Contents
Slide 3: Indication, Dosage, and Administration
Dr. Jeffrey Farma provides his insight on treating the elderly patient population in the surgical oncology setting.
This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.
This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|